Shuttle Pharmaceuticals (NASDAQ:SHPH) Announces Quarterly Earnings Results

Shuttle Pharmaceuticals (NASDAQ:SHPH) issued its earnings results on Tuesday. The company reported $0.06 earnings per share (EPS) for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Stock Performance

Shares of SHPH opened at $0.67 on Thursday. The firm has a fifty day moving average of $1.22 and a 200-day moving average of $2.12. The company has a market cap of $1.08 million, a price-to-earnings ratio of -0.06 and a beta of -0.52. Shuttle Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $13.75.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Connective Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the 3rd quarter worth about $357,000. Ikarian Capital LLC bought a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter valued at approximately $124,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, Geode Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth approximately $26,000. 4.58% of the stock is currently owned by institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .